awmsg logo



entecavir (Baraclude®)


Reference No. 438

Publication date:
08/03/2012


Appraisal information

entecavir (Baraclude®) 0.5 mg film-coated tablet
entecavir (Baraclude®) 0.05 mg/ml oral solution
entecavir (Baraclude®) 1 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category: Infections
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0212
Ministerial ratification: 08/03/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Entecavir (Baraclude®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B virus infection in adults with decompensated liver disease. Oral solution should only be used in circumstances where the tablet form is not a clinical option. Treatment should normally be initiated following dialogue with a specialist liver unit. AWMSG is of the opinion that entecavir (Baraclude®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download